Analysts think FGEN stock price could increase by 138%
Aug 07, 2024, 6:26 AM
-6.60%
What does FGEN do
FibroGen, Inc., a biopharmaceutical company based in San Francisco, develops novel therapeutics using HIF biology and CTGF biology, focusing on treatments for anemia, fibrotic diseases, and cancer. Their key product, Roxadustat, is approved in China, Europe, and Japan for treating anemia due to CKD and is under development for other anemia conditions and chemotherapy-induced anemia.
4 analysts think FGEN stock price will increase by 138.16%. The current median analyst target is $1.07 compared to a current stock price of $0.45. The lowest analysts target is $0.61 and the highest analyst target is $1.58.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.